Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 20/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 15/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 15/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 15/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7653971 | 1.00 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL7659147 | 1.00 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL7653976 | 1.00 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL7662809 | 0.94 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL6773194 | 0.94 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18840948 | 0.94 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7667502 | 0.93 | CCR3 (0.89) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7667508 | 0.93 | CCR3 (0.89) | CCR3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6773307 | 0.91 | CCR3 (1.00) | CCR3SLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL26079496 | 0.91 | CCR3 (0.91) | CCR3SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118653851-A | Method for preventing and controlling rock burst of cavern by lancing and releasing pressure | 福州大学 | 2024-09-17 | — | — | CN | claimed |
| US-6441001-B1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-27 | — | — | US | claimed |
| US-12598801-B2 | Semiconductor device of physical unclonable function and manufacturing method thereof | TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) | 2026-04-07 | — | — | US | disclosed |
| US-20240387524-A1 | SEMICONDUCTOR DEVICE AND MANUFACTURING METHOD THEREOF | TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) | 2024-11-21 | — | — | US | disclosed |
| CN-118653851-A | Method for preventing and controlling rock burst of cavern by lancing and releasing pressure | 福州大学 | 2024-09-17 | — | — | CN | disclosed |
| CN-118534025-A | Iridium isotope fingerprint-based organic mass spectrometry probe for detecting nitric oxide | 四川大学 | 2024-08-23 | — | — | CN | disclosed |
| CN-116202320-A | Pressure rail ring type gangue decarburizing machine | 北京中宏联工程技术有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-218994014-U | Pressure rail ring type gangue decarburizing machine | 北京中宏联工程技术有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-218994056-U | Non-pressure rail ring type gangue decarburizing machine | 北京中宏联工程技术有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-112605147-B | High-corrosion-resistance and low-potential fin aluminum foil for heat exchanger and manufacturing method thereof | 江苏鼎胜新能源材料股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-11530979-B2 | Multifocal photoacoustic microscopy through an ergodic relay | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-12-20 | — | — | US | disclosed |
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-05-11 | — | — | US | disclosed |
| US-6441001-B1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | CCR3, CCR5, CCR1 | CCR3 1/4885SLC6A2 2615/4885SLC6A4 2372/4885 |
| US-12598801-B2 | Semiconductor device of physical unclonable function and manufacturing method thereof | PIEZO1, CTCF, GJB2 | CCR3 3991/4885SLC6A2 1332/4885SLC6A4 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.